ClinicalTrials.gg

Program

Atorvastatin

Also written as “atorvastatin”, “Atorvastatin 20 mg” and “Comparator: atorvastatin”.

Its studies are mostly in Hypercholesterolemia · Dyslipidemias · Hyperlipidemias · Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 22 companies.

Furthest: phase 4, since Aug 30, 2005105 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatris290 open or runningphase 4since Aug 30, 2005Aug 25, 2005none ahead
Organon200 open or runningphase 4since Apr 1, 2008Sep 23, 2004none ahead
Pfizer160 open or runningphase 4since Sep 6, 2005Aug 22, 2005none ahead
Chong Kun Dang Pharmaceutical60 open or runningphase 4since Nov 16, 2009Nov 16, 2009none ahead
Dr. Reddy's Laboratories60 open or runningphase 1since Jul 18, 2012Jul 18, 2012none ahead
GlaxoSmithKline60 open or runningphase 3since Dec 15, 2011Dec 11, 2006none ahead
Astellas Pharma30 open or runningphase 4since Dec 5, 2006Dec 5, 2006none ahead
Daiichi Sankyo30 open or runningphase 4since Sep 16, 2008Sep 16, 2008none ahead
midas-pharma-gmbh20 open or runningphase 1since Jan 23, 2020Jan 23, 2020none ahead
Sun Pharmaceutical Industries20 open or runningphase 1since Dec 20, 2011Dec 20, 2011none ahead
Azidus Brasil10 open or runningphase 1since Sep 21, 2012Sep 21, 2012none ahead
clinical-research-management-inc10 open or runningphase 2since Mar 1, 2015Mar 1, 2015none ahead
Cumberland Pharmaceuticals10 open or runningphase 2since Jul 19, 2018Jul 19, 2018none ahead
Daewon Pharmaceutical10 open or runningphase 3since Jul 24, 2023Jul 24, 2023none ahead
Daewoong Pharmaceutical10 open or runningphase 3since Oct 26, 2016Oct 26, 2016none ahead
dr-md-alimur-reza10 open or runningphase 4since Jan 17, 2025Jan 17, 2025none ahead
Huons Global11 open or runningphase 1since Aug 5, 2026Aug 5, 2026Apr 2027phase 1 · NCT07784608
Intarcia Therapeutics10 open or runningphase 1since Dec 21, 2015Dec 21, 2015none ahead
Jeil Pharmaceutical10 open or runningphase 1since Mar 5, 2018Mar 5, 2018none ahead
Laboratorios Silanes S.A. de C.V.10 open or runningphase 3since Apr 29, 2021Apr 29, 2021none ahead
Profil Institut für Stoffwechselforschung10 open or runningphase 1since Sep 9, 2009Sep 9, 2009none ahead
samil-pharmaceutical-co-ltd10 open or runningphase 1since Oct 13, 2015Oct 13, 2015none ahead

Also a collaborator on its studies: parexel, pharma-medica-research-inc, Merck, Regeneron Pharmaceuticals, mds-pharma-services, celerion, Sanofi and basilea-pharmaceutica-international-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since Mar 26, 2008.

  1. Oct 26, 2016Daewoong Pharmaceutical's first study: phase 3 study in Diabetes Mellitus, Type 2New to Daewoong PharmaceuticalDaewoong Pharmaceutical · NCT02947620 · 185 enrolled · Korea, Republic of
  2. Nov 27, 2016Phase 2 study in DyslipidemiasChong Kun Dang Pharmaceutical · NCT02977065 · 62 enrolled · Australia
  3. Jan 23, 2017Phase 1 study in Non-alcoholic Fatty Liver DiseasePfizer · NCT03031119 · 62 enrolled · Belgium
  4. Mar 5, 2018Jeil Pharmaceutical's first study: phase 1 study in Hypertension With HyperlipidemiaNew to Jeil PharmaceuticalJeil Pharmaceutical · NCT03461081 · 32 enrolled · Korea, Republic of
  5. Jul 19, 2018Cumberland Pharmaceuticals's first study: phase 2 study in HypercholesterolemiaNew to Cumberland PharmaceuticalsCumberland Pharmaceuticals · NCT03611010 · 40 enrolled · United States
  6. Mar 6, 20193 phase 3 studiesOrganon · NCT03884452, NCT03867318, NCT03867110
  7. Jan 23, 2020midas-pharma-gmbh's first study: phase 1 study in Healthy VolunteersNew to midas-pharma-gmbhmidas-pharma-gmbh · NCT04245046 · 18 enrolled · Jordan
  8. Feb 7, 2020Phase 1 study in Healthy Volunteersmidas-pharma-gmbh · NCT04262765 · 18 enrolled · Jordan
  9. Apr 29, 2021Laboratorios Silanes S.A. de C.V.'s first study: phase 3 study in DyslipidemiasNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT04882293 · 78 enrolled · Mexico
  10. Oct 13, 2021Phase 1 study in Healthy AdultsPfizer · NCT05093205 · 35 enrolled · United States
  11. Jul 24, 2023Daewon Pharmaceutical's first study: phase 3 study in HypercholesterolemiaNew to Daewon PharmaceuticalDaewon Pharmaceutical · NCT05970679 · 252 enrolled · Korea, Republic of
  12. Jan 17, 2025dr-md-alimur-reza's first study: phase 4 study in HyperlipidemiasNew to dr-md-alimur-rezadr-md-alimur-reza · NCT06789432 · Bangladesh
  13. Nov 14, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07235189, NCT07268625
  14. Aug 5, 2026Huons Global's first study: phase 1 study in Drug-drug InteractionsNew to Huons GlobalHuons Global · NCT07784608 · 28 planned · South Korea

Ahead

  1. Apr 2027Primary completion: phase 1 study in Drug-drug InteractionsHuons Global · NCT07784608

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
rosuvastatinruleAstraZenecaphase 4184
SimvastatinruleOrganonphase 4100
pitavastatinruleKowaphase 436

Studies

The newest 60 of 105 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07784608Drug-drug Interactions · South Korea1Not yet recruitingHuons GlobalApr 202728
NCT07268625Healthy Subjects · Portugal1CompletedDaiichi SankyoFeb 24, 202658
NCT07235189Healthy Subjects · Portugal1CompletedDaiichi SankyoJan 28, 202658
NCT06789432Hyperlipidemias · Bangladesh4Withdrawndr-md-alimur-rezaOct 20250
NCT05970679Hypercholesterolemia · Korea, Republic of3CompletedDaewon PharmaceuticalApr 13, 2023252
NCT05093205Healthy Adults · United States1CompletedPfizerJul 6, 202235
NCT04882293Dyslipidemias · Mexico3UNKNOWNLaboratorios Silanes S.A. de C.V.May 202278
NCT04262765Healthy Volunteers · Jordan1Completedmidas-pharma-gmbhMar 26, 201918
NCT04245046Healthy Volunteers · Jordan1Completedmidas-pharma-gmbhFeb 18, 201918
NCT03884452Hyperlipoproteinemia Type II3CompletedOrganonMay 24, 200150
NCT03867318Hypercholesterolemia3CompletedOrganonNov 16, 2001621
NCT03867110Hypercholesterolemia3CompletedOrganonJul 27, 2001628
NCT03611010Hypercholesterolemia · United States2CompletedCumberland PharmaceuticalsFeb 17, 202040
NCT03461081Hypertension With Hyperlipidemia · Korea, Republic of1CompletedJeil PharmaceuticalJul 12, 201732
NCT03031119Non-alcoholic Fatty Liver Disease · Belgium1CompletedPfizerJul 201762
NCT02977065Dyslipidemias · Australia2CompletedChong Kun Dang PharmaceuticalDec 30, 201762
NCT02947620Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedDaewoong PharmaceuticalFeb 27, 2017185
NCT02641899Healthy · United States1CompletedIntarcia TherapeuticsMar 201633
NCT02579356Essential Hypertension · Korea, Republic of1Completedsamil-pharmaceutical-co-ltdAug 201448
NCT02550288Hypercholesterolemia3CompletedOrganonMay 30, 2016309
NCT02460159Hypercholesterolemia3CompletedOrganonDec 22, 2016135
NCT02422030Healthy · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalMar 22, 201530
NCT02380625Hemorrhagic Fever, Ebola2UNKNOWNclinical-research-management-incJan 2016150
NCT02295046Healthy · Germany1CompletedDr. Reddy's LaboratoriesOct 201180
NCT02292069Healthy · India1CompletedDr. Reddy's LaboratoriesSep 201190
NCT02288338Healthy · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalFeb 201536
NCT02066207Dyslipidemias · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalApr 7, 201430
NCT01964326Hypercholesterolemia · United States3CompletedViatrisDec 20141,311
NCT01842256Essential Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalMay 201324
NCT01692717Healthy Subjects · Brazil1CompletedAzidus BrasilMay 31, 201390
NCT01645449Healthy · Germany1CompletedDr. Reddy's LaboratoriesAug 201077
NCT01645423Healthy · India1CompletedDr. Reddy's LaboratoriesSep 200977
NCT01645410Healthy · India1CompletedDr. Reddy's LaboratoriesApr 200971
NCT01645384Healthy · India1CompletedDr. Reddy's LaboratoriesJun 200969
NCT01635946Pharmacokinetics of Isavuconazole · United States1CompletedAstellas PharmaAug 201224
NCT01499771Healthy · United States1CompletedSun Pharmaceutical IndustriesOct 200980
NCT01499758Healthy · United States1CompletedSun Pharmaceutical IndustriesOct 200980
NCT01495013Diabetes Mellitus, Type 2 · Korea, Republic of, Malaysia, Mexico and more3CompletedGlaxoSmithKlineApr 2013427
NCT01370603Hypercholesterolemia3CompletedOrganonMay 2012328
NCT01370590Hypercholesterolemia3CompletedOrganonApr 2012406
NCT01218204Dyslipidemias · United States2CompletedGlaxoSmithKlineJun 29, 2011287
NCT01299597Sleep Wake Disorders · Germany1CompletedGlaxoSmithKlineFeb 26, 201030
NCT01154036Hypercholesterolemia3CompletedOrganonSep 20121,547
NCT01138072Infections · United States1CompletedGlaxoSmithKlineAug 201014
NCT01115985Healthy · Japan1CompletedAstellas PharmaApr 201024
NCT01029522Dyslipidemias4CompletedChong Kun Dang PharmaceuticalOct 2008244
NCT00974740Diabetes Mellitus, Type 1 · Germany1TerminatedProfil Institut für StoffwechselforschungJan 200863
NCT00917579Hypercholesterolemia · United States4CompletedViatrisSep 200876
NCT00871351Primary Hypercholesterolemia4CompletedOrganonMay 1, 2010125
NCT00844376Hypercholesterolemia · United States4CompletedViatrisMar 200812
NCT00827606Hyperlipoproteinemia Type II · United States, Belgium, Canada and more3CompletedViatrisOct 2013272
NCT00782184Hypercholesterolemia3CompletedOrganonSep 2010250
NCT00758004Hypercholesterolemia · United States1CompletedViatrisMar 200976
NCT00754507Hypercholesterolemia · United States4CompletedDaiichi SankyoJun 200365
NCT00739999Pediatric Heterozygous Hypercholesterolemia · Canada, Greece, Norway1CompletedViatrisMay 200939
NCT00728988Acute Coronary Syndrome · China, Korea, Republic of4CompletedViatrisApr 2010499
NCT00654095Hypercholesterolemia3CompletedOrganonJun 1, 2009146
NCT00653796Hypercholesterolemia4CompletedOrganonAug 1, 2004148
NCT00650689Hypercholesterolemia3CompletedOrganonDec 2004122
NCT00647543Dyslipidemias · Thailand4CompletedViatris242

How it is read

Names in the registry

  • “Atorvastatin”, 95 entries
  • “atorvastatin”, 36 entries
  • “Atorvastatin 20 mg”, 3 entries
  • “Comparator: atorvastatin”, 3 entries
  • “Atorvastatin 10 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.